Eris Lifesciences · NSE: ERIS · BSE: 540596
Q2 FY23 results · Jul–Sep 2022
Eris Lifesciences reported revenue from operations of ₹460.51 crore (up 28.0% from Q2 FY22) and net profit of ₹119.38 crore (up 0.8% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 460.51 | 359.67 | +28.0% | 398.58 | +15.5% |
| Other income | 5.17 | 6.99 | −25.9% | 2.74 | +89.0% |
| Total income | 465.68 | 366.66 | +27.0% | 401.32 | +16.0% |
| Profit before tax | 120.93 | 130.78 | −7.5% | 101.27 | +19.4% |
| Net profit for the period | 119.38 | 118.39 | +0.8% | 93.08 | +28.3% |
| Attributable to shareholders of the company | 120.30 | 118.39 | +1.6% | 94.58 | +27.2% |
| EPS, basic (₹) | 8.84 | 8.71 | +1.5% | 6.96 | +27.0% |
| Net margin (%) | 25.9 | 32.9 | 23.4 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 355.37 | 322.66 | +10.1% | 328.76 | +8.1% |
| Other income | 6.15 | 7.65 | −19.6% | 3.37 | +82.5% |
| Total income | 361.52 | 330.31 | +9.4% | 332.13 | +8.8% |
| Profit before tax | 123.81 | 132.29 | −6.4% | 107.36 | +15.3% |
| Net profit for the period | 115.20 | 119.71 | −3.8% | 95.59 | +20.5% |
| EPS, basic (₹) | 8.47 | 8.81 | −3.9% | 7.03 | +20.5% |
| Net margin (%) | 32.4 | 37.1 | 29.1 |
Consolidated
- Filed with BSE
- 20 Oct 2022, 16:22 IST
- Board meeting
- 20 Oct 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 20 Oct 2022, 16:22 IST
- Board meeting
- 20 Oct 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE